Skip to content

Delcath Systems DCTH U.S. — Product revenue

Similar metrics at other companies

Aurinia Pharmaceuticals logo
AUPHU.S. — Revenue
$65.96M+25.6%
Nuvation Bio logo
NUVBUS — Revenue
$77.39M
Axogen logo
AXGNU.S. — Revenue
$60.13M+25.7%
Inspire Medical Systems logo
INSPUnited States — Revenue
$195.6M+1.0%
Organon logo
OGNU.S. — Revenue
$358M-13.1%
PROCEPT BioRobotics Corporation logo
PRCTU.S. — Revenue
$72.02M+19.4%

Other financials

Income statement

See full
Revenue$25.0M+26.3%
Gross profit$21.3M+25.5%
Operating income-$1.6M-355%
Net income-$1.1M-200%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$41.3M+223%
Total debt$907.0K-10.7%
Total equity$112.7M+40.5%
Total assets$124.8M+43.0%

Cash flow

See full
Operating cash flow$857.0K-61.1%
CapEx$570.0K+307%
Free cash flow$287.0K-86.1%

Valuation

See full
Market cap$425.31M-11.8%
Enterprise value$384.91M-18.2%
P/E120.6×
P/S4.7×-4.3×

Profitability

See full
Gross margin86%+1.1pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin21.2%+15.2pp

Returns & leverage

See full
Return on equity1.9%+1.0pp
Debt / equity0.0×
Current ratio11.2×-4.7×

Where this comes from

Reported directly by Delcath Systems in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's u.s. — product revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Delcath Systems's U.S. — product revenue?
Delcath Systems (DCTH) reported U.S. — product revenue of $23.25M in Q1 2026.
How has Delcath Systems's U.S. — product revenue changed year-over-year?
Delcath Systems's U.S. — product revenue increased by 29.0% year-over-year, from $18.02M to $23.25M.
What does U.S. — product revenue mean?
This metric measures the total gross income generated from the sale of products within the U.S. market segment. It serves as a primary indicator of commercial adoption and market penetration for the company's therapeutic offerings. Tracking this figure helps evaluate the growth trajectory and revenue-generating capacity of the domestic business unit.